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Philippe Erbs5, Jessica C. Hassel2, Christof von Kalle3, Alexander H. Enk2, Dirk M. Nettelbeck1,2,8 and
Guy Ungerechts3,6,8
Effective treatment modalities for advanced melanoma are desperately needed. An innovative approach is
virotherapy, in which viruses are engineered to infect cancer cells, resulting in tumor cell lysis and an
amplification effect by viral replication and spread. Ideally, tumor selectivity of these oncolytic viruses is already
determined during viral cell binding and entry, which has not been reported for melanoma. We engineered an
oncolytic measles virus entering melanoma cells through the high molecular weight melanoma–associated
antigen (HMWMAA) and proved highly specific infection and spread in melanoma cells. We further enhanced
this oncolytic virus by inserting the FCU1 gene encoding the yeast-derived prodrug convertases cytosine
deaminase and uracil phosphoribosyltransferase. Combination treatment with armed and retargeted MV-FCU1-
aHMWMAA and the prodrug 5-fluorocytosine (5-FC) led to effective prodrug conversion to 5-fluorouracil,
extensive cytotoxicity to melanoma cells, and excessive bystander killing of noninfected cells. Importantly,
HMWMAA-retargeted MV showed antitumor activity in a human xenograft mouse model, which was further
increased by the FCU1/5-FC prodrug activation system. Finally, we demonstrated susceptibility of melanoma skin
metastasis biopsies to HMWMAA-retargeted MV. The highly selective, entry-targeted and armed oncolytic virus
MV-FCU1-aHMWMAA may become a potent building block of future melanoma therapies.
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INTRODUCTION
Malignant melanoma is the most common form of fatal skin
cancer (Siegel et al., 2012) and incidences continue to rise
(MacKie et al., 2009). Although the recent approval of the
targeted therapeutics vemurafenib (Heakal et al., 2011) and
ipilimumab (Cameron et al., 2011) is encouraging, for
advanced malignant melanoma no curative therapy is
currently available, creating an urgent need for effective
combination therapies.
An emerging approach to treat cancer is oncolytic virother-
apy (Russell et al., 2012). Viruses of various families are being
engineered to specifically infect and replicate in tumor cells,
whereas healthy cells are spared (Figure 1a). In the course of
infection, the therapeutic agent is locally amplified, spreads,
and tumor cells are destroyed by viral cell lysis. Moreover,
viral oncolysis has been reported to trigger systemic antitumor
immune activation (Boisgerault et al., 2010). Ideally, oncolytic
viruses are genetically modified to bind and enter tumor cells
only. This has not been reported to date for malignant
melanoma and is a major aim of our study.
A highly promising molecule for targeted melanoma ther-
apy is the high molecular weight melanoma–associated
antigen (HMWMAA, also called MCSP or CSPG-4), as
490% of melanomas are HMWMAA-positive with limited
intratumoral heterogeneity and retained expression in
advanced disease (Campoli et al., 2010). In combination
with restricted distribution in normal tissues, this has
encouraged the development of diagnostic antibodies and
HMWMAA-targeted immunotherapeutic agents (Campoli
et al., 2010).
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We and others have shown that derivatives of the measles
virus (MV) vaccine strain, Edmonston B, have high oncolytic
potency on various tumor entities (Galanis, 2010) which is
currently investigated in clinical trials (Russell et al., 2012).
Target cells are recognized by the MV attachment protein
hemagglutinin (H) that can be engineered to bind to a specific
tumor surface marker of interest by destroying the natural
receptor tropism (Nakamura et al., 2004; Vongpunsawad
et al., 2004) while adding a new target cell specificity by
the fusion of single-chain antibodies (single-chain variable
fragment, scFv’s, (Nakamura et al., 2005)).
In addition to causing tumor cell lysis, oncolytic MVs have
been utilized to deliver therapeutic transgenes (Ungerechts
et al., 2007b; Li et al., 2010). Prodrug-activating enzymes are
of special interest, as they can locally convert innocuous
prodrugs into chemotherapeutically active drugs in infected
tumor cells (Figure 1a). This strategy aims at producing higher
drug concentrations in the tumor than reached after systemic
drug application in conventional chemotherapy. The combi-
nation of viral oncolysis and prodrug activation is coined
chemovirotherapy and has proven to be efficient in various
tumor models (Ungerechts et al., 2007a; Bossow et al., 2011;
Zaoui et al., 2012). A popular prodrug activation system
is based on cytosine deaminase (CD) converting
5-fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU,
(Portsmouth et al., 2007)). The FCU1 gene encodes a fusion
protein of yeast CD (encoded by FCY1) and yeast uracil
phosphoribosyltransferase (UPRT, encoded by FUR1). UPRT
catalyzes the activation of 5-FU into 5-FU monophosphate, a
function frequently diminished in tumor cells rendering them
resistant to 5-FU treatment (Erbs et al., 2000). Yeast CD, either
by itself (yCD) or in combination with UPRT (yCD-UPRT),
has been successfully used in context of various oncolytic
viruses (Nakamura et al., 2001; Fuerer and Iggo, 2004;
Conrad et al., 2005; Chalikonda et al., 2008; Foloppe et al.,
2008; Dias et al., 2010; Quirin et al., 2011), but not in
oncolytic MVs.
In this study we developed a targeted chemovirotherapy for
malignant melanoma. We constructed an MV displaying an
scFv directed against HMWMAA, and analyzed specificity
and oncolytic efficacy in melanoma cell cultures, in a
xenograft mouse model, and in biopsies of melanoma metas-
tases. We investigated whether therapeutic efficacy in vitro
and in vivo is significantly enhanced by arming the retargeted
oncolytic MV with FCY1 or FCU1, and subsequent prodrug
application.
RESULTS
Generation of HMWMAA-retargeted MV
We constructed a recombinant MV based on the Edmonston B
vaccine strain by modifying the attachment glycoprotein H to
both ablate natural viral tropism toward CD46 and SLAM
(Vongpunsawad et al., 2004) and introducing a melanoma-
directed tropism through C-terminal fusion of an scFv binding
HMWMAA (RAFT3, (Kang et al., 2000)). To monitor virus
infection, an additional transcription unit encoding the
enhanced green fluorescent protein (EGFP) was inserted
into the genome upstream of the nucleoprotein (N) gene
(MV-EGFP-aHMWMAA, Figure 1b). Control viruses contained
an unmodified H (MV-EGFP) or H directed against
the lymphoma-associated antigen CD20 (MV-EGFP-aCD20,
(Ungerechts et al., 2007a)).
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Figure 1. Concept of chemovirotherapy and recombinant measles virus (MV) genomes. (a) Schematic outline of chemovirotherapy. An entry-targeted and armed
MV specifically infects tumor cells, leading to syncytia formation, viral replication and spread, and ultimately tumor cell death. In infected tumor areas, the prodrug
convertase is expressed, allowing for activation of innocuous prodrug into active drug, and thus combined oncolysis and bystander killing of uninfected
neighboring cells. Modified after Kaufmann and Nettelbeck (2012) with permission of Elsevier. (b) Schematic representation of recombinant MV genomes. Vectors
contain either an unmodified hemagglutinin (H) or a receptor-blinded H retargeted toward HMWMAA and CD20, respectively, and a transgene X. Transgenes are
inserted behind the leader and encode enhanced green fluorescent protein (EGFP), yeast cytosine deaminase (yCD), or yCD in combination with uracil
phosphoribosyltransferase (yCD-UPRT). Names of corresponding viruses are stated at the bottom right.
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Melanoma-specific infectivity of HMWMAA-retargeted MV
Expression of the modified H by MV-EGFP-aHMWMAA-
infected cells was verified by western blot analysis
(Figure 2a). In MV producer cells, Vero-aHis, the expression
levels of retargeted HaHMWMAA were comparable with
those of the previously reported HaCD20 control.
To proof specific transduction of melanoma cells, we
infected a panel of cell lines expressing either HMWMAA or
CD20 with MV-EGFP-aHMWMAA and with the control
viruses (Figure 2b). In cell culture, MV infection and spread
manifest in a cytopathic effect (CPE) by formation of multi-
nucleated syncytia due to the fusion of infected cells with
neighboring cells. After infection of three melanoma cell lines
and the low-passage melanoma cells pMelL with MV-EGFP-
aHMWMAA, we detected CPE by typical, broad syncytia
formation comparable to that after infection with MV-EGFP
(Figure 2b, upper panel). In contrast, CPE for HMWMAA-
negative cells was visible upon infection with MV-EGFP only
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Figure 2. Specificity of oncolysis and replication of high molecular weight melanoma–associated antigen (HMWMAA)-retargeted measles virus (MV).
(a) Detection of hemagglutinin (H) and nucleoproteins (N) by western blot analysis of Vero-aHis lysates infected with indicated viruses at a multiplicity of
infection (MOI) of 1 for 24 hours. (b) Melanoma cell cultures and control cells were infected with indicated viruses at MOI 0.5. Pictures of enhanced green
fluorescent protein (EGFP) fluorescence and phase contrast were taken 120 hours post infection (p.i.) and merged (top, bar ¼ 200mm). The surface expression
of HMWMAA and CD20 was determined by flow cytometry (bottom). Growth kinetics for (c) MV-EGFP-aHMWMAA and MV-EGFP in Mel888 cells (MOI 3),
and for (d) MV-EGFP-aHMWMAA and MV-EGFP-aCD20 in Mel888 and HT1080-CD20 cells (MOI 3). Total viral particles were collected at indicated time
points and titrated on Vero-aHis cells.
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(with the exception of Vero-aHis cells, see below). The CD20-
targeted control virus could infect CD20-positive cells, but not
HMWMAA-expressing cells. Thus, infection patterns matched
the surface expression of the two target antigens, as deter-
mined by FACS analysis (Figure 2b, bottom panel). The MV
producer cell line, Vero-aHis, was highly susceptible to all
three viruses because of the presence of both CD46, the
natural receptor for unmodified MV-EGFP, and a pseudore-
ceptor for the His6-tag in retargeted MV H variants. For this
cell line, syncytia formation had already been followed by
complete cell lysis at 120 hours post infection (p.i.). Vero cells
expressed HMWMAA at low levels and, consequently, were
weakly susceptible to melanoma-retargeted MV.
In conclusion, the infection pattern and CPE of MV-EGFP-
aHMWMAA correlated with antigen expression, demonstrating
its target cell specificity and success of our MV entry–targeting
strategy for melanoma using the HMWMAA-specific scFv.
Replication efficiency and selectivity of HMWMAA-retargeted
MV
To assess a possible impact of retargeting on viral replication,
we analyzed one-step growth kinetics of MV-EGFP-aHMW-
MAA and MV-EGFP control virus on Mel888 melanoma cells.
Titration of progeny particles revealed a growth delay for the
retargeted MV, whereas comparable maximal titers were
eventually reached 72 hours p.i. (Figure 2c). In addition, we
compared the selective replication potential of MV-EGFP-
aHMWMAA and the CD20-targeted control virus on both
HMWMAA-positive Mel888 and antigen-negative HT1080-
CD20 cells. MV-EGFP-aCD20 replicated efficiently in
HT1080-CD20, but was strongly attenuated in Mel888 cells.
Conversely, MV-EGFP-aHMWMAA produced high virus titers
in Mel888, whereas replication was attenuated almost 1,000-
fold on HMWMAA-negative HT1080-CD20, underlining its
exceptional target cell specificity.
Characterization and cytotoxicity of yCD-armed
HMWMAA-retargeted MVs for chemovirotherapy
To enhance cytotoxicity of the melanoma-specific oncolytic
MV, the EGFP reporter gene was exchanged by yeast-derived
genes encoding the prodrug-activating enzymes yCD (FCY1)
or yCD-UPRT (FCU1, Figure 1b). The expression of yCD,
yCD-UPRT, and EGFP by HMWMAA-retargeted viruses
was verified by western blot analysis (Supplementary
Figure S1a online). Analyzing growth kinetics of these armed
viruses in comparison with MV-EGFP-aHMWMAA demon-
strated all viruses to replicate equally (Supplementary
Figure S1b online).
Next we compared the cytotoxic impacts of the two armed
variants in melanoma cells, A375M and Mel888. At 96 hours
p.i., virus-mediated cytotoxicity could clearly be detected with
the more pronounced effects on Mel888 cells (Figure 3a). On
addition of 5-FC 24 hours p.i., cell killing was drastically
enhanced after MV-FCU1-aHMWMAA infection of both cell
lines. The most marked effect was observed for A375M cells.
Here cell killing by combined oncolysis and prodrug activa-
tion was 81.0–99.6% dependent on the viral dose. Cell killing
with the MV-FCU1-aHMWMAA/5-FC combination treatment
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Figure 3. Cytotoxicity of prodrug convertase-armed, high molecular weight
melanoma–associated antigen (HMWMAA)-retargeted measles virus (MV).
Melanoma cell lines A375M and Mel888 were infected with indicated viruses
and multiplicities of infection (MOIs), or were mock-infected for 24 hours
and then treated with 5-fluorocytosine (5-FC), 5-fluorouracil (5-FU), or
medium. Cell viability was determined 96 hours post infection (p.i.). Means
and SDs of quadruplicate infections are shown; viability of mock-treated
cells was set to 100%. (a) 5-FC and 5-FU were used at 1,000mM. *Po0.001
(two-way analysis of variance (ANOVA) as compared with respective infected
cells not treated with 5-FC). (b) Cells were infected at MOI 1. 5-FU was used at
1,000mM, 5-FC was used at doses from 10 to 1,000mM. *Po0.001 (one-way
ANOVA as compared with mock-infected, 5-FC-treated cells); N.S.,
nonsignificant.
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was equally potent than that of the control treatment with
5-FU for both multiplicity of infection (MOI) 3 and 1 on both
cell lines, alluding to effective prodrug activation. Cytotoxicity
exerted by MV-FCY1-aHMWMAA was clearly less enhanced
by the prodrug.
Treatment efficacy of combined MV-FCU1-aHMWMAA/5-
FC proved not only to be dependent on viral doses, but also
on the 5-FC concentration as shown for A375M and Mel888
cells (Figure 3b).
Bystander killing by MV-FCU1-aHMWMAA in combination with
5-FC
An important feature of the yCD/5-FC prodrug activation
system is based on the diffusibility of 5-FU, enabling a toxic
bystander effect on neighboring and more distant tumor cells
that have not been infected initially. We tested this phenom-
enon in vitro by infection of cells (converting cells) and
subsequent prodrug addition. Supernatants were collected
upon complete lysis of the cell layer and viral particles were
heat-inactivated. Subsequently, serial dilutions were trans-
ferred onto newly seeded A375M cells (bystander cells). After
treatment of converting cells, 5-FU in the supernatant then
exerts cytotoxicity on bystander cells. We first tested bystander
activity of the superior yCD-UPRT-armed virus with Vero-aHis
cells as converting cell line and, thus, independent of entry
through HMWMAA. Supernatants from MV-FCU1-aHMW-
MAA/5-FC-treated cells elicited marked, dose-dependent cell
killing similar to equal dilutions of 5-FU (Figure 4). In contrast,
neither mock-infected nor MV-EGFP-aHMWMAA-treated
cells produced cytotoxic supernatants when supplied with
5-FC. Furthermore, supernatants from cells infected with
yCD-UPRT-armed virus, but not treated with prodrug, did
not transfer cytotoxicity. These controls show that prodrug
conversion was virus-dependent, and that inactivation of
viruses in the transferred supernatants was successful. In
addition, we confirmed the bystander activity of MV-FCU1-
aHMWMAA in a more relevant setting by using A375M and
Mel888 melanoma cell lines as converting cells. Again,
cytotoxicity similar to the 5-FU-treated positive control was
reached, demonstrating virtually complete prodrug conversion
in melanoma cells after chemovirotherapy.
Oncolysis and chemovirotherapy with HMWMAA-retargeted
MVs in vivo
To assess the efficacy of a chemovirotherapeutic regimen
in vivo, we subcutaneously engrafted human A375M tumors
in NOD/SCID mice. When reaching an average volume of
50 mm3, tumors were injected on 5 consecutive days with
1.44 105 cell infectious units MV-FCU1-aHMWMAA, MV-
EGFP-aHMWMAA, or carrier fluid. Starting 3 days after the
last virus injection, 200 mg kg 1 5-FC or saline were adminis-
tered intraperitoneally twice daily on 5 consecutive days.
Measurement of tumor volumes revealed a highly significant
growth retardation of virus-treated xenografts when compared
with control groups. Demonstrating effective oncolysis in vivo,
this translated into a significant extension of median survival
from 43 to 54 days (Figure 5a). Average tumor volumes and
survival did not differ between armed and reporter virus-
treated groups. However, no additional prodrug activation
effect was observed.
We then modified the regimen by starting treatment at an
average tumor volume of 40 mm3, doubling the viral dose,
and administering 5-FC earlier, i.e., on days 1 to 5 after the
last virus application. With this regimen, we could reproduce
the highly significant oncolysis-only effect of MV-FCU1-
aHMWMAA (Figure 5b). The expression of yCD-UPRT and
viral N mRNAs in xenografts was confirmed (Supplementary
Figure S2 online). Most notably, we observed a clear and
highly significant additional prodrug activation effect on both
tumor growth and survival. Thus, our schedule-adjusted
chemovirotherapy represents a beneficial treatment regimen
in this model of melanoma.
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Figure 4. Bystander cytotoxicity of MV-FCU1-aHMWMAA/5-fluorocytosine (5-FC). Vero-aHis, A375M, or Mel888 cells were infected with indicated viruses at
multiplicity of infection (MOI) 0.1 and treated with 1,000mM 5-FC or medium at 36 hours post infection (p.i; Vero-aHis), 72 hours p.i. (A375M), or 60 hours p.i.
(Mel888), respectively. Supernatants were collected 12 hours (Vero-aHis, Mel888) or 24 hours (A375M) later on complete lysis of the cell layer, and were heat-
inactivated. Serial dilutions were transferred onto fresh A375M in quadruplicates and viability was determined 72 hours later. Means and SDs are shown; viability
of mock-infected cells was set to 100%. Equivalent dilutions of 5-fluorouracil (5-FU) served as controls. *Po0.001 (two-way analysis of variance as compared with
respective cells treated with supernatant not supplied with 5-FC); N.S., nonsignificant.
JK Kaufmann et al.
Chemovirotherapy of Malignant Melanoma
1038 Journal of Investigative Dermatology (2013), Volume 133
Infection of biopsies of human melanoma metastases with
HMWMAA-retargeted MV
Importantly, we validated infection and spread of the entry-
targeted oncolytic MV in highly relevant human primary
material. Biopsies of melanoma skin metastases were sec-
tioned into living tissue slices, infected with MV-EGFP-
aHMWMAA, and reporter gene expression was detected by
fluorescence microscopy. We could show that melanoma
metastasis tissue was readily infectable with retargeted MV
(Figure 6a). In parallel, we established a monolayer cell
culture originating from the same metastasis. These freshly
purified melanoma cells strongly expressed HMWMAA
(Figure 6b, bottom panel). Infection with MV-EGFP-aHMW-
MAA led to extended syncytia formation (Figure 6b, upper
panel), resulting in complete eradication of the cell monolayer
within 96 hours p.i.. Infection was confirmed in living
tissue slices from a melanoma skin metastasis biopsy of a
second patient (not shown). Taken together, susceptibility
of primary melanoma material supports the suitability of
the HMWMAA-retargeted oncolytic MV for treatment of
advanced melanoma.
DISCUSSION
In this study, we have established an entry-targeted oncolytic
virus for treatment of malignant melanoma. HMWMAA-
retargeted MV showed highly specific infection of and spread
in melanoma cell lines and in biopsies of melanoma metas-
tases. Cytotoxicity in vitro and therapeutic activity in a
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Figure 5. Oncolysis and chemovirotherapy with high molecular weight melanoma–associated antigen (HMWMAA)-retargeted measles viruses (MVs) in vivo.
NOD/SCID mice harboring subcutaneous A375M xenografts were treated with five daily intratumoral virus injections or mock injections, followed by
intraperitoneal injections of 5-fluorocytosine (5-FC) or saline twice daily on 5 consecutive days as indicated. Tumor volumes (left, middle) and survival (right) were
monitored. Left: ***Po0.001 (two-way analysis of variance (ANOVA), mock vs. every virus). Middle: ***Po0.001 (unpaired t-test). (a) Virus injections started
when mean tumor volume was 50 mm3 with daily doses of 1.44 105 cell infectious units (ciu). Right: Po0.0001 (log-rank test, survival distributions of mock vs.
each virus-treated group). (b) Virus injections started when mean tumor volume was 40 mm3, with daily doses of 3.05 105 ciu. Left: yyyPo0.001 (two-way
ANOVA, MV-FCU1-aHMWMAA vs., MV-FCU1-aHMWMAAþ 5-FC). Middle: **P¼ 0.0025, yP¼ 0.0106 (unpaired t-test). Right: P¼ 0.0024 (log-rank test, mock
vs. MV-FCU1-aHMWMAA), P¼ 0.0037 (log-rank test, MV-FCU1-aHMWMAA vs. MV-FCU1-aHMWMAAþ5-FC).
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melanoma xenograft model were further increased by arming
with FCU1.
Our study demonstrates MV susceptibility in a panel of
established and low-passage melanoma cell cultures. In line
with the results of a recent study with untargeted MV-EGFP
(Donnelly et al., 2011), we observed various degrees of
cytotoxicity. Thus, combination of MV-mediated oncolysis
with other therapeutic regimens is essential. Indeed, MV
oncolysis is highly suitable for combination regimens, as the
mode of cell killing differs from established therapies. Here we
report that chemovirotherapy is an effective approach to
achieve complete cell killing of melanoma cell lines that
have different sensitivities to MV-mediated oncolysis alone.
In addition to molecular chemotherapy, antitumor immune
activation has high potential to increase the therapeutic
impact of oncolytic viruses. In fact, a recent study has
demonstrated that untargeted MV induces immunogenic cell
death in human melanoma cells triggering activation of innate
and adaptive antitumor responses (Donnelly et al., 2011).
This supports the relevance of intratumoral injection of our
HMWMAA-targeted MV, followed by systemic antitumor
immunity for clinical translation. In this line, our observation
of infection and spread of HMWMAA-targeted MV in biopsies
of melanoma skin metastases provides a rationale for injecting
skin metastases of melanoma patients, followed by monitoring
of oncolysis and immune responses.
HMWMAA is an appealing antigen for targeted therapies, as
it is expressed not only on cells making up the tumor bulk, but
also on cells maintaining melanoma growth (Campoli et al.,
2010). In addition, HMWMAA is expressed on activated
pericytes in various tumor tissues (Schlingemann et al.,
1990). This may in fact be beneficial as implied by
HMWMAA-directed vaccination studies in mice in which
tumor neovascularization was impaired, whereas side effects
in other tissues were not observed (Maciag et al., 2008).
To enhance the therapeutic potential of the melanoma-
specific MV, we inserted the FCU1 gene (yeast CD-UPRT
fusion protein) into the virus genome. This resulted in
efficient conversion of 5-FC into chemotherapeutic 5-FU and
its active metabolites, bystander activity, and complementa-
tion of MV oncolysis in vitro. Our results for melanoma
reveal that yCD-UPRT activity is superior to that of yCD alone
and to bacterial CD-UPRT (not shown). This is accordant
with a systematic evaluation of yeast and bacterial
5-FC-mediated prodrug activation systems identifying
yCD-UPRT as the most effective enzyme combination
(Johnson et al., 2011).
5-FU is typically not included in melanoma chemothera-
peutic regimens. However, melanoma cell lines are highly
susceptible to 5-FU treatment in vitro (Quirin et al., 2011). In
fact, the aim of our chemovirotherapeutic approach is to
achieve locally effective 5-FU concentrations while
minimizing 5-FU-related systemic side effects. It is
noteworthy that the FCU1-encoded UPRT activity converts
5-FU into its active metabolites, further increasing the
sensitivity and overcoming resistance of melanoma cells to
5-FU (Quirin et al., 2011).
The in vitro results of the present study are in accordance
with our recent report on effectivity of yCD-UPRT/5-FC
prodrug activation in melanoma in combination with untar-
geted oncolytic adenoviruses (Quirin et al., 2011).
Importantly, we now show that prodrug activation is
similarly functional in melanoma in vivo, augmenting the
antitumor activity of the HMWMAA-retargeted MV. The
combined chemovirotherapy only proved to be beneficial
when virus treatment began at 40 mm3 mean tumor volume,
and when 5-FC application was started 1 day after the last
virus administration. This emphasizes the importance of the
exact application regimen, and as shown for other
chemovirotherapeutic settings there is room for improvement
with respect to timing and time span of prodrug administration
(Yamada et al., 2012), as well as number and timing of
multiple treatment cycles (Ungerechts et al., 2010).
In summary, MV-FCU1-aHMWMAA is a highly selective
and potent oncolytic MV for chemovirotherapy of malignant
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Figure 6. Infection of explanted human melanoma skin metastasis by high
molecular weight melanoma–associated antigen (HMWMAA)-retargeted
measles virus (MV). An excised human melanoma skin metastasis, cultivated
as living tissue slices (a) and freshly purified melanoma cells (b), were infected
with 106 cell infectious unit MV-EGFP-aHMWMAA per slice or at multiplicity
of infection (MOI) 0.5, respectively. Pictures were taken 72 hours post infection
(p.i.). HMWMAA expression on primary cells was detected by flow cytometry
(b, bottom panel). Bar ¼ 200mm.
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melanoma showing efficient cell killing in vitro and therapeu-
tic activity in vivo. The unique combination of oncolysis
involving syncytia formation, bystander killing by prodrug
activation, and induction of immunogenic cell death
(Donnelly et al., 2011) may give an advantage over other
virotherapeutic approaches for this disease. Corroborated by
our infection studies of living primary human melanoma
metastasis slices, further investigations shall support the
translation of HMWMAA-retargeted MV toward clinical trials
of virotherapy and chemovirotherapy for malignant
melanoma.
MATERIALS AND METHODS
Cell culture
Human melanoma cultures (A375M, Mel888, pMelL, and SK-MEL-
28) and cell lines Vero, Vero-aHis, HT1080-CD20, and Raji were
previously described (Nettelbeck et al., 2004; Ungerechts et al.,
2007a).
Generation of recombinant MVs
Genomic MV cDNA plasmids are based on the Edmonston B vaccine
lineage strain with an additional transcription unit between leader
and N gene. Here the transgenes EGFP, FCY1, and FCU1 (Erbs et al.,
2000) were inserted. The scFv fragment against HMWMAA (RAFT3,
(Kang et al., 2000)) was C-terminally fused to a receptor-blinded H
protein and incorporated into the viral genomes. For details, see
Supplementary Materials and Methods section.
Recombinant MV particles were generated from cDNA constructs
and amplified on Vero-aHis cells, as described previously (Nakamura
et al., 2005; Martin et al., 2006). To prepare virus stocks, Vero-aHis
cells were infected at MOI 0.03 and incubated at 32 1C for 58 hours.
Viral particles were collected and titers were determined, as
previously described (Bossow et al., 2011).
Infection
All infection experiments were conducted with viral stocks from the
fourth passage. Cell lines were infected with the respective MV at
indicated MOIs in Opti-MEM (Life Technologies, Darmstadt, Ger-
many) for 2 hours at 37 1C, followed by exchange to standard
medium. Infected cells were photographed using the Cell Observer
fluorescence microscope and Axiovision 4.7 software (both from
Zeiss, Jena, Germany), scraped into their medium for analysis of
growth kinetics, or subjected to cell viability assay.
Western blot
Vero-aHis cells (5 104 per 24 well) were infected at MOI 1. Cells
were collected 24 hours p.i., lysed, denatured at 96 1C for 10 minutes,
and subjected to SDS–PAGE electrophoresis and immunoblotting, as
described before (Quirin et al., 2011). Membranes were probed with
polyclonal rabbit-anti-H and rabbit-anti-N antibodies (kind gifts of
R. Cattaneo, Mayo Clinic, Rochester, MN). Proteins were detected
with respective horseradish peroxidase-conjugated secondary
antibody (Cell Signaling Technologies, Beverly, MA) and visualized
using Pierce ECL reagents (Thermo Fisher Scientific, Bonn, Germany).
FACS analysis
Surface expression was determined using monoclonal antibodies
against HMWMAA (clone 9.2.27; Millipore, Schwalbach/Ts,
Germany) and CD20 (clone 2H7; BD Biosciences, Heidelberg,
Germany) at 5mg ml 1 in phosphate-buffered saline, 10% fetal calf
serum, 0.01% NaN3. Isotype controls (IgG2a clone MOPC-173 and
IgG2b clone MPC-11; BioLegend, Uithoorn, The Netherlands) and
unconjugated antibodies were detected with polyclonal PE-coupled
goat-anti-mouse secondary antibody (BD Biosciences; 0.5mg ml 1).
Samples were analyzed using FACSort (BD Biosciences) and FCS
Express Version 3 (De Novo Software, Los Angeles, CA).
One-step growth curves
Cells (105 per 12 well) were infected at MOI 3 in duplicates. Cells
were scraped into their medium at indicated time points and
subjected to one freeze-thaw cycle. Total viral particles were titrated
as mentioned above.
Cytotoxicity and bystander assays
For cytotoxicity and bystander assays, 104 cells per 96 well or 4 105
cells per 6 well were infected. 5-FC, 5-FU (both from Sigma,
Steinheim, Germany), or medium was administered at indicated
concentrations and time points. For measurement of bystander
activity, converting cell supernatants were heat-inactivated at 60 1C
for 30 minutes. Serial dilutions were transferred onto freshly seeded
cells (104 per 96 well). Viability of cells was measured by the cell
proliferation kit III (XTT; PromoKine, Heidelberg, Germany), accord-
ing to the manufacturer’s protocol. Sample and reference absorbances
were measured using Labsystems Multiskan MS and Ascent Software
2.6 (both from Thermo Fisher Scientific) at wavelengths of 477 and
620 nm.
Xenograft model
All animal experimental procedures were approved by the respon-
sible Animal Protection Officer at the German Cancer Research
Center and by the regional authorities, according to the German
Animal Protection Law. A375M cells (107) were implanted subcuta-
neously into right flanks of 6- to 8-week-old female NOD/SCID mice
(Charles River, Sulzfeld, Germany). On an average volume of 40 or
50 mm3, tumors were injected with 1.44 105 or 3.05 105 viral
particles per dose or Opti-MEM on 5 consecutive days (n¼ 10).
Mice were then intraperitoneally injected with 200 mg kg 1 5-FC or
saline twice daily on 5 consecutive days at the indicated time points.
Tumor volumes ((largest diameter) (smallest diameter)2 0.5) and
weight were monitored every third day. Animals were killed
when tumor volumes exceeded 1,500 mm3 or on weight loss of
more than 20%.
Human biopsy material
Human melanoma skin metastasis biopsies were obtained according
to the Declaration of Helsinki Principles and to the local Ethics
Committee’s guidelines, with informed consent from the Department
of Dermatology, University Hospital Heidelberg, Germany. Tissues
were sliced and cultivated as previously described (Zimmermann
et al., 2012), and infected with 106 viral particles per slice. For
establishment of primary cell cultures, blocks of melanoma tissue
were cultivated in primary melanoma medium (Nettelbeck et al.,
2004) and regularly washed to eliminate all debris and cells in
suspension until an adherent cell layer had formed. Fibroblast growth
was suppressed by 100mg ml 1 gentamycin medium supplement.
Experiments were conducted after 10 passages.
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